Trial Profile
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Acronyms OPTIC-X
- Sponsors Horizon Pharma USA
- 18 Jun 2023 Results of pooled analysis from European Study Sites Participating in the Phase 2, OPTIC (Phase 3) and OPTIC-X trials , presented at the 105th Annual Meeting of the Endocrine Society
- 18 May 2022 Results from two 24-week trials assessing quantify QALY improvements with teprotumumab, we correlated and bridged GO-QOL values with TTO-derived utility scores presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 01 Apr 2022 Results published in the Ophthalmology